Vertex Pharmaceuticals Incorporated
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Vertex Pharmaceuticals Incorporated generated cash of $3,537,300,000, which is less than the previous year. Cash used in financing activities reached the amount of -$562,200,000 last year. Net change in cash is therefore -$139,700,000.
Cash Flow
| 2014 | -513.19M | 73.95M | 497.37M |
|---|---|---|---|
| 2015 | -365.43M | 268.85M | 188.91M |
| 2016 | 236.10M | 104.46M | 133.27M |
| 2017 | 844.94M | -437.68M | 68.40M |
| 2018 | 1.27B | -202.15M | -71.21M |
| 2019 | 1.56B | -1.23B | 126.77M |
| 2020 | 3.25B | 99.38M | -505.28M |
| 2021 | 2.64B | -340.9M | -1.47B |
| 2022 | 4.12B | -321.1M | -67.7M |
| 2023 | 3.53B | -3.14B | -562.2M |
0QZU.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 10.51B | 6.80B | 5.98B | 3.12B | 2.65B | 1.66B | 1.18B | 714.76M | 625.25M | 569.29M |
Operating activities | ||||||||||
Net income | 3.61B | 3.32B | 2.34B | 2.71B | 1.17B | 2.08B | 91.63M | -84.03M | -588.18M | -742.74M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 181.3M | 148.3M | 125.6M | 109.51M | 106.94M | 72.42M | 61.39M | 61.39M | 62.34M | 63.25M |
Stock-based compensation expense | 581.2M | 491.3M | 441.4M | 429.5M | 360.48M | 0 | 290.73M | 237.70M | 231.02M | 177.54M |
| Deferred income tax benefit | 581.2M | 491.3M | 441.4M | 429.5M | 360.48M | 0 | 290.73M | 237.70M | 231.02M | 177.54M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -84.1M | -358.6M | -274.7M | -223.44M | -225.58M | -108.15M | -71.75M | -33.02M | -104.84M | 7.42M |
Inventories | -322.9M | -136.4M | -92.8M | -132.01M | -64.04M | -31.96M | -44.98M | -16.45M | -23.14M | -16.46M |
Accounts payable | 48.7M | 120.8M | 31.9M | 51.27M | -22.78M | 36.55M | 8.75M | -11.74M | -1.70M | 25.04M |
Cash generated by operating activities | 3.53B | 4.12B | 2.64B | 3.25B | 1.56B | 1.27B | 844.94M | 236.10M | -365.43M | -513.19M |
Investing activities | ||||||||||
Purchases Of Investments | -3.81B | -740.5M | -605.2M | -450.72M | -576.51M | -515.38M | -532.58M | -629.7M | -633.04M | -1.42B |
Investments In Property Plant And Equipment | -200.4M | -204.7M | -235M | -259.8M | -75.45M | -95.52M | -259.42M | -56.56M | -45.30M | -51.20M |
Acquisitions Net | 0 | -295.9M | 76.99M | -418.24M | -1.15B | 0 | -160M | 0 | -80M | -10M |
Cash generated by investing activities | -3.14B | -321.1M | -340.9M | 99.38M | -1.23B | -202.15M | -437.68M | 104.46M | 268.85M | 73.95M |
Financing activities | ||||||||||
Common Stock Issued | 134.6M | 186.3M | 102M | 264.94M | 343.24M | 289.29M | 344.84M | 68.23M | 185.59M | 274.61M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -427.6M | -172M | -1.56B | -739.40M | -192.01M | -350.04M | 0 | 0 | 0 | 0 |
Repayments of term debt | -43.1M | -82M | -47M | -42.27M | -29.13M | -33.38M | -284.67M | -93.02M | 3.32M | -81.69M |
Cash used in financing activities | -562.2M | -67.7M | -1.47B | -505.28M | 126.77M | -71.21M | 68.40M | 133.27M | 188.91M | 497.37M |
Net Change In Cash | -139.7M | 3.71B | 811.2M | 2.86B | 462.42M | 990.72M | 481.46M | 469.17M | 89.50M | 55.96M |
Cash at end of period | 10.37B | 10.51B | 6.80B | 5.98B | 3.12B | 2.65B | 1.66B | 1.18B | 714.76M | 625.25M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |